Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata
- Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications
- ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia Areata
- Health Authorities in Canada and the United States provided swift CTA & IND approval allowing for efficient dosing of the first patients
Boston, Massachusetts and Lausanne, Switzerland, 27 March 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces that the first patient has been dosed in its Phase IIa trial of ALY-101 in patients suffering from Alopecia Areata (AA), a chronic autoimmune disease with significant unmet medical need that often leads to significant psychological distress and a reduced quality of life.
